BRPI0518424A2 - derivados de 2,4 (4,6) pirimidina - Google Patents
derivados de 2,4 (4,6) pirimidinaInfo
- Publication number
- BRPI0518424A2 BRPI0518424A2 BRPI0518424-0A BRPI0518424A BRPI0518424A2 BR PI0518424 A2 BRPI0518424 A2 BR PI0518424A2 BR PI0518424 A BRPI0518424 A BR PI0518424A BR PI0518424 A2 BRPI0518424 A2 BR PI0518424A2
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- het
- piperazinyl
- hydrogen
- pyrrolidinyl
- Prior art date
Links
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title abstract 2
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004193 piperazinyl group Chemical group 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000002757 morpholinyl group Chemical group 0.000 abstract 4
- 125000003386 piperidinyl group Chemical group 0.000 abstract 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 2
- 125000002971 oxazolyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Abstract
DERIVADOS DE 2,4 (4,6) PIRIMIDINA. A presente invenção refere-se a compostos da fórmula. As formas de N-óxido, os sais de adição farmaceuticamente aceitáveis e as formas estereoquimicamente isoméricas dos mesmos, em que: Z¹ e Z² representa NH; Y representa -C~ 3-9~ alquila-, -C~ 3-9~ alquenila-, -C~ 1-5~ alquil-NR^ 6^-C~ 1-5~ alquila-, -C~ 1-5~ alquil-NR^ 7^-CO-C~ 1-5~ alquila-, -C~ 1-6~ alquil-CO-NH-, -C~ 1-6~ alquil- NH-CO-, -C~ 1-2~ alquil-CO-Het^ 10^-CO-, -C~ 1-3~ alquil-NH-CO-Hetü-, -Het^ 4^-C.~ 1-3~ alquil-CO-NH-C~ 1-3~ alquila-, -C~ 1-2~ alquil-NH-CO-L¹-NH-, -NH-CO-L²-NH-, -C~ 1-2~ alquil-CO-NH-Lü-CO-, -C~ 1-2~ alquil-NH-CO-L¹-NH-CO-C~ 1-3~ alquila-, -C~ 1-2~ alquil- CO-NH-Lü-CO-NH-C~ 1-3~ alquila-, -C~ 1-2~ alquil-NR¹¹-CH~ 2~-CO-NH-C~ 1-3~ alquila-, Het^ 5^-CO-C~ 1-2~ alquila, -C~ 1-5~ aIquiI-CO-NH-C~ 1-3~ alquil-CO-NH-, -C~ 1-5~ alquil- NR¹ü-CO-C~ 1-3~ alquil-NH-, -C13 alquil-NH-CO-Het^ 27^-CO- ou -C~ 1-3~ alquil-CO- Het^ 28^-CO-NH-; X¹ representa uma ligação direta, O, -O-C~ 1-2~ alquila-, -CO-C~ 1-2~ alquila-, -NR^ 16^-C~ 1-2~ alquila-, -CO-NR^ 17^-, Het^ 23^-C~ 1-2~ alquila- ou C~ 1-2~ alquila; X² representa uma ligação direta, O, -O-C~ 1-2~ alquila-, -CO-C~ 1-2~ alquila-, -NR^ 18^-C~ 1-2~ alquila-, -CO-NR^ 19^-, Het^ 24^-C~ 1-2~ alquila- ou C~ 1-2~ alquila; R¹ e R^ 5^ representam, cada um independentemente, hidrogênio, halo, C~ 1-6~ alquilóxi- ou C~ 1-6~ alquilóxi- substituído por Het¹ ou C~ 1-4~ alquilóxi-; R² e R^ 4^ representam, cada um independentemente, hidrogênio ou halo; Rü representa hidrogênio ou ciano; R^ 6^, R^ 7^, R^ 13^, R^ 17^ e R^ 19^ representam hidrogênio; R¹¹ representa hidrogênio ou C~ 1-4~ alquila; R^ 16^e R^ 18^ representa hidrogênio, C~ 1-4~ alquila ou Het^ 17^-C~ 1-4~ alquila-; L¹, L¹ e Lü representam, cada um independentemente, C~ 1-8~ alquila opcionalmente substituida por um ou, onde possível, dois ou mais substituintes selecionados de fenita, metil-sulfeto, ciano, C~ 1-4~ polihaloalquil- fenila-, C~ 1-4~ alquilóxi, piridinila, mono- ou di(C~ 1-4~ alquil)-amino- ou C~ 3-6~ ciclo alquila; Het¹, Het², Het^ 17^ representam, cada um independentemente, morfolinila, oxazolila, isoxazolila ou piperazinila; Hetü, Het^ 4^, Het^ 5^ representam, cada um independentemente, mor- folinila, piperazinila, piperidinila ou pirrolidinila; Het^ 10^ representa piperazinila, piperidinila, pirrolidinila ou azetidinila; Het²² representa morfolinila, oxazolila, isoxazolila ou piperazinila em que o referido Het²² é opcionalmente substituido por C~ 1-4~ alquila; Het²ü e Het^ 24^ representam, cada um independentemente, um heterociclo selecionado de pirrolidinila, piperazinila ou piperidinila em que os referidos Het²ü ou Het^ 24^ são opcionalmente substituidos por Het²²-carbonila; Het^ 27^ e Het^ 28^ representam, cada um independentemente, um heterociclo selecionado de morfolinila, piperazinila, piperidinila ou pirrolidinila.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63429104P | 2004-12-08 | 2004-12-08 | |
| EP04106384.3 | 2004-12-08 | ||
| EP04106384 | 2004-12-08 | ||
| US60/634,291 | 2004-12-08 | ||
| PCT/EP2005/056606 WO2006061415A1 (en) | 2004-12-08 | 2005-12-08 | 2,4 (4,6) pyrimidine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0518424A2 true BRPI0518424A2 (pt) | 2008-11-25 |
| BRPI0518424B1 BRPI0518424B1 (pt) | 2020-10-13 |
| BRPI0518424B8 BRPI0518424B8 (pt) | 2021-05-25 |
Family
ID=34930016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0518424A BRPI0518424B8 (pt) | 2004-12-08 | 2005-12-08 | derivados de 2,4 (4,6) pirimidina, composição farmacêutica que os compreende, intermediários e uso dos mesmos |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8148388B2 (pt) |
| EP (1) | EP1824856B1 (pt) |
| JP (1) | JP5022909B2 (pt) |
| KR (1) | KR101428506B1 (pt) |
| CN (1) | CN101072779B (pt) |
| AR (1) | AR051788A1 (pt) |
| AU (1) | AU2005313348B2 (pt) |
| BR (1) | BRPI0518424B8 (pt) |
| CA (1) | CA2588761C (pt) |
| CR (1) | CR9234A (pt) |
| DK (1) | DK1824856T3 (pt) |
| EA (1) | EA013368B1 (pt) |
| ES (1) | ES2442458T3 (pt) |
| IL (1) | IL183706A0 (pt) |
| MX (1) | MX2007006821A (pt) |
| MY (1) | MY169441A (pt) |
| NO (1) | NO340130B1 (pt) |
| NZ (1) | NZ554820A (pt) |
| TW (1) | TWI374140B (pt) |
| UA (1) | UA90693C2 (pt) |
| WO (1) | WO2006061415A1 (pt) |
| ZA (1) | ZA200705040B (pt) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004298448B2 (en) | 2003-12-18 | 2010-09-09 | Janssen Pharmaceutica N.V. | Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents |
| AU2005271161B2 (en) * | 2004-08-10 | 2011-05-12 | Janssen Pharmaceutica N.V. | HIV inhibiting 1,2,4-triazin-6-one derivatives |
| NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
| JO3088B1 (ar) * | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
| CN101360751B (zh) | 2005-11-16 | 2011-09-14 | S*Bio私人有限公司 | 氧连接的嘧啶衍生物 |
| CA2654583C (en) | 2006-07-13 | 2015-11-24 | Janssen Pharmaceutica N.V. | Mtki quinazoline derivatives |
| WO2008060248A1 (en) * | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
| AU2008281849B2 (en) | 2007-07-27 | 2013-11-28 | Janssen Pharmaceutica Nv | Pyrrolopyrimidines |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| JP5600063B2 (ja) | 2007-10-19 | 2014-10-01 | セルジーン アビロミクス リサーチ， インコーポレイテッド | ヘテロアリール化合物およびその使用 |
| WO2009112439A1 (en) * | 2008-03-10 | 2009-09-17 | Janssen Pharmaceutica Nv | 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors |
| CA2722326A1 (en) * | 2008-04-24 | 2009-10-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| ES2668834T3 (es) * | 2008-09-08 | 2018-05-22 | Merck Serono Sa | Pirimidinas macrociclicas como inhibidores de proteína quinasas |
| US8765727B2 (en) | 2009-01-23 | 2014-07-01 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| JP2012197231A (ja) * | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体 |
| BR112012029647A2 (pt) | 2010-05-21 | 2016-08-02 | Chemilia Ab | novos derivados de pirimidinas |
| BR112013010564B1 (pt) | 2010-11-01 | 2021-09-21 | Celgene Car Llc | Compostos heterocíclicos e composições compreendendo os mesmos |
| WO2012074951A1 (en) * | 2010-11-29 | 2012-06-07 | OSI Pharmaceuticals, LLC | Macrocyclic kinase inhibitors |
| MX2013010898A (es) | 2011-03-24 | 2013-12-06 | Chemilia Ab | Novedoso derivados de la pirimidina. |
| ES2880109T3 (es) | 2012-03-15 | 2021-11-23 | Celgene Car Llc | Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico |
| JP6317320B2 (ja) | 2012-03-15 | 2018-04-25 | セルジーン シーエーアール エルエルシー | 上皮成長因子受容体キナーゼ阻害剤の塩 |
| EP2994471B1 (en) * | 2013-05-06 | 2017-05-17 | Merck Patent GmbH | Macrocycles as kinase inhibitors |
| MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
| MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
| US9708324B2 (en) * | 2015-02-05 | 2017-07-18 | Merck Patent Gmbh | Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof |
| CA3057891A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| EP3601253B1 (en) | 2017-03-28 | 2021-09-15 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| ES2963356T3 (es) * | 2019-06-12 | 2024-03-26 | Nouryon Chemicals Int Bv | Método para aislar ácido carboxílico a partir de una corriente lateral acuosa |
| JP7281564B2 (ja) | 2019-06-12 | 2023-05-25 | ヌーリオン ケミカルズ インターナショナル ベスローテン フェノーツハップ | 過酸化ジアシルを生成するためのプロセス |
| JP7335362B2 (ja) | 2019-06-12 | 2023-08-29 | ヌーリオン ケミカルズ インターナショナル ベスローテン フェノーツハップ | 過酸化ジアシルを生成するためのプロセス |
| JP7281563B2 (ja) | 2019-06-12 | 2023-05-25 | ヌーリオン ケミカルズ インターナショナル ベスローテン フェノーツハップ | ペルオキシエステルを生成するためのプロセス |
| US11976035B2 (en) | 2019-06-12 | 2024-05-07 | Nouryon Chemicals International B.V. | Process for the production of diacyl peroxides |
| US12594277B2 (en) * | 2020-02-14 | 2026-04-07 | Salk Institute For Biological Studies | Macrocyclic ULK1/2 inhibitors |
| CN113549113A (zh) * | 2020-06-17 | 2021-10-26 | 广州百霆医药科技有限公司 | 一种含膦大环化合物及其制备方法与应用 |
| JP2024546154A (ja) * | 2021-12-15 | 2024-12-17 | ワン イン ファーマシューティカル カンパニー リミテッド | 大環状ピリミジン誘導体、その製造方法、及び、それを活性成分として含む神経変性疾患の予防又は治療のための医薬組成物 |
| KR102613509B1 (ko) * | 2021-12-15 | 2023-12-13 | 환인제약 주식회사 | 마크로사이클릭 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신경 퇴행성 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5438299A (en) * | 1998-08-29 | 2000-03-21 | Astrazeneca Ab | Pyrimidine compounds |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| IL166241A0 (en) * | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| JO2785B1 (en) | 2003-05-27 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinazoline derivatives |
| AU2004298448B2 (en) | 2003-12-18 | 2010-09-09 | Janssen Pharmaceutica N.V. | Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents |
| EA200601176A1 (ru) | 2003-12-18 | 2006-10-27 | Янссен Фармацевтика Н.В. | 3-цианохинолиновые производные с антипролиферативной активностью |
-
2005
- 2005-12-06 MY MYPI20055703A patent/MY169441A/en unknown
- 2005-12-07 AR ARP050105123A patent/AR051788A1/es unknown
- 2005-12-07 TW TW094143059A patent/TWI374140B/zh not_active IP Right Cessation
- 2005-12-08 BR BRPI0518424A patent/BRPI0518424B8/pt active IP Right Grant
- 2005-12-08 ES ES05819148.7T patent/ES2442458T3/es not_active Expired - Lifetime
- 2005-12-08 CA CA2588761A patent/CA2588761C/en not_active Expired - Lifetime
- 2005-12-08 NZ NZ554820A patent/NZ554820A/en not_active IP Right Cessation
- 2005-12-08 KR KR1020077011771A patent/KR101428506B1/ko not_active Expired - Lifetime
- 2005-12-08 EA EA200701245A patent/EA013368B1/ru not_active IP Right Cessation
- 2005-12-08 JP JP2007544917A patent/JP5022909B2/ja not_active Expired - Lifetime
- 2005-12-08 CN CN2005800420717A patent/CN101072779B/zh not_active Expired - Lifetime
- 2005-12-08 US US11/720,681 patent/US8148388B2/en active Active
- 2005-12-08 MX MX2007006821A patent/MX2007006821A/es active IP Right Grant
- 2005-12-08 WO PCT/EP2005/056606 patent/WO2006061415A1/en not_active Ceased
- 2005-12-08 UA UAA200705051A patent/UA90693C2/ru unknown
- 2005-12-08 EP EP05819148.7A patent/EP1824856B1/en not_active Expired - Lifetime
- 2005-12-08 DK DK05819148.7T patent/DK1824856T3/da active
- 2005-12-08 AU AU2005313348A patent/AU2005313348B2/en not_active Expired
-
2007
- 2007-06-06 IL IL183706A patent/IL183706A0/en active IP Right Grant
- 2007-06-07 ZA ZA200705040A patent/ZA200705040B/xx unknown
- 2007-07-06 CR CR9234A patent/CR9234A/es not_active Application Discontinuation
- 2007-07-09 NO NO20073492A patent/NO340130B1/no unknown
-
2011
- 2011-10-20 US US13/277,651 patent/US8394955B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0518424B8 (pt) | derivados de 2,4 (4,6) pirimidina, composição farmacêutica que os compreende, intermediários e uso dos mesmos | |
| BRPI0718966B8 (pt) | composto, composição farmacêutica, inibidor plk1 e agente antitumoral | |
| CO6190513A2 (es) | Compuestos tetrahidrociclopenta [b] indol como moduladores del receptor de androgenos | |
| BRPI0909731A2 (pt) | derivados de carbazol inibidores de hsp90, composições que os contêm e a respectiva utilização | |
| MY153393A (en) | Amino nicotinic and isonicotinic acid derivatives as dhodh as inhibitors | |
| NO20053596L (no) | Adamantylacetamider som 11-beta hydroksysteroid-dehydrogenaseinhibitorer | |
| ATE442356T1 (de) | 1-essigsäureindolderivate mit pgd2- antagonistischer wirkung | |
| EA200601177A1 (ru) | Пиридо- и пиримидопиримидиновые производные в качестве антипролиферативных агентов | |
| EP2597088A4 (en) | P2X4 Receptor Antagonists | |
| NO20051051L (no) | Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme i terapeutiske midler | |
| NO20065184L (no) | 1-amino-ftalazinderivater, deres fremstilling og terapeutiske anvendelse derav | |
| JP2013507434A5 (pt) | ||
| WO2008051533A3 (en) | Benzimidazole compounds | |
| NO20072053L (no) | Nye bis-azaindolderivater, fremstilling og farmasoytisk anvendelse derav som kinaseinhibitorer | |
| EA200701233A1 (ru) | Производные хиназолина в качестве mtki | |
| MY153042A (en) | Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | |
| AU2008235282A8 (en) | Quinolines and their therapeutic use | |
| MY146939A (en) | Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics | |
| BR0308759A (pt) | Derivados de fenil amidas siliconadas utilizáveis como microbiocida | |
| WO2009106750A3 (fr) | Dérivés 6-heterocyclique-imidazo[1,2-a]pyrroine-2-carboxamides, leur préparation et leur application en thérapeutique | |
| WO2009115651A3 (fr) | Composés de n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique | |
| MX2011011246A (es) | Derivados de 1-h-pirazolo [4,3-c] isoquinoleinas, su preparacion y su uso en terapeutica. | |
| BRPI0509564A (pt) | derivados pirrolo(2,3-b)piridina, respectivo preparo e respectiva utilização farmacêutica como inibidores de quinases | |
| AR071688A1 (es) | Derivados de pirrol, su preparacion y su aplicacion en terapeutica | |
| TW200942539A (en) | N-phenylimidazo[1,2-α]pyridine-2-carboxamide derivatives, their preparation and their therapeutic application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |